functional dyspepsia

From Aaushi
Jump to navigation Jump to search

Introduction

At least 3 months of pain or discomfort centered in the upper abdomen, without clinical, endoscopic, or ultrasonographic evidence of known organic disease likely to explain the symptoms.

Etiology

(differential diagnosis)

* 75% of cases are due to GERD &/or IBS

Pathology

* essentially the same disorder as gastroparesis[4]

Clinical manifestations

* essentially the same disorder as gastroparesis[4]

Diagnostic criteria

Laboratory

Management

More general terms

Additional terms

References

  1. Jump up to: 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17, 18. American College of Physicians, Philadelphia 1998, 2015, 2018
  2. Jump up to: 2.0 2.1 van Zanten SV et al, Esomeprazole 40 mg once a day in patients with functional dyspepsia: The radomized, placebo-controlled 'ENTER' trial. Am J Gastroenterol 2006, 101:2096 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16817845
  3. Lacy BE, Talley NJ, Locke GR 3rd et al Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012 Jul;36(1):3-15. Epub 2012 May 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22591037
  4. Jump up to: 4.0 4.1 4.2 Pasricha PJ et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathologic features. Gastroenterology 2021 May; 160:2006. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33548234 https://www.gastrojournal.org/article/S0016-5085(21)00337-1/fulltext
    Tack J et al. Gastroparesis: A dead-end street after all? Gastroenterology 2021 May; 160:1931. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33621562 https://www.gastrojournal.org/article/S0016-5085(21)00432-7/fulltext
  5. Hamza Z Probiotics Show Promise for Symptoms of Functional GI Disorders. Small pilot study suggested clinical benefit, acceptable safety profile. https://www.medpagetoday.com/gastroenterology/generalgastroenterology/93951
    Wauters L, Slaets H, De Paepe K et al Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021; Aug 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34358486 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00226-0/fulltext
    Burns GL, Hoedt EC, Keely S Spore-forming probiotics for functional dyspepsia. Lancet Gastroenterol Hepatol 2021; Aug 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34358485 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00260-0/fulltext